- In patients with relapsed/refractory multiple myeloma (R/R MM), the major predictor of durable response to lenalidomide-dexamethasone (Ld) was achievement of partial response (PR) or better following the first treatment cycle.
Why this matters
- Lenalidomide-based triplet combinations are superior to Ld in patients with R/R MM, but Ld is still considered a standard of care in select patients.
- Multicenter study to identify characteristics predictive of durable response to Ld (n=227) in R/R MM.
- 11% had prior known clonal plasma cell disorder in the form of smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS).
- Funding: None disclosed.
- 37% were identified as durable responders (defined as PFS of ≥24 months).
- Baseline characteristics associated with PFS >24 months in multivariate analysis:
- Standard cytogenetics: HR=2.86, P=.049.
- MGUS/MM: HR=3.02, P=.049.
- Treatment in first relapse: HR=2.07, P=.031.
- Characteristics associated with PFS >24 months when including achievement of partial remission in cycle 1 in multivariate analysis:
- Prior history of MGUS/SMM: HR=5.4, P=.006.
- PR after cycle 1: HR=6.9, P<.001.>
- Retrospective data.